summer street

Shares of MannKind Corp. (NASDAQ: MNKD) fall as much as 27.105% prior to Tuesday's Endocrinologic and Metabolic Drugs Advisory Committee Meeting. Piper Jaffray analyst Joshua Schimmer noted that MannKind faces a "number of obstacles" in the U.S. Food and Drug Administration's (FDA) review of...

Shares of MannKind (NASDAQ: MNKD) are down approximately 2 percent amid comments from Summer Street analyst Bart Classen. Classen reported in an interview that MannKind's briefing documents may be “problematic” regarding Affinity 1 studies on the Afrezza Dreamboat insulin inhaler. The analyst...

Shares of Ariad Pharmaceuticals (NASDAQ: ARIA) responded following an early Friday formal announcement that the company has U.S. approval to bring Inclusig back to the market, and will begin to sell by mid- January. Ariad shares hit $7.75, up 40 percent. Ariad said, "The USPI includes a revised...

Avanir Pharmeceuticals (NASDAQ: AVNR) stock plummeted yesterday after Gravity Research said Avanir, “engaged in illegal off-label marketing of Nuedexta,” and recommended a strong Sell. Shares closed at $4.79 on Wednesday, a 13 percent decrease. This was the biggest drop of AVNR in three years...

Summer Street initiated coverage on Lpath Incorporated (NASDAQ: LPTN) with a Buy rating and an $18 price target. Summer Street noted, "Lpath's valuation is compelling when compared to other platform companies in similar positions. Our iSONEP royalty projections begin in 2017 at $28MM and grow to...

Summer Street initiates its coverage on Dendreon (NASDAQ: DNDN) with a Buy rating and a $18 price target. Summer Street comments, "DNDN's stock has declined >80% since the company announced slower than expected Provenge adoption and lowered prior 2011 revenue guidance during the 2Q11 earnings...

According to a research report published earlier today, Summer Street has initiated Synergy Pharmaceuticals (NASDAQ: SGYP) with a Buy rating and $9 PT. Summer Street said in the report, “We believe SGYP's lead compound, plecanatide, has great potential to become the second, but best-inclass,...

Summer Street has downgraded Wright Medical (NASDAQ: WMGI) from Neutral to Sell.